Schmidt B

References (16)

Title : Single-molecule sequencing to track plasmid diversity of hospital-associated carbapenemase-producing Enterobacteriaceae - Conlan_2014_Sci.Transl.Med_6_254ra126
Author(s) : Conlan S , Thomas PJ , Deming C , Park M , Lau AF , Dekker JP , Snitkin ES , Clark TA , Luong K , Song Y , Tsai YC , Boitano M , Dayal J , Brooks SY , Schmidt B , Young AC , Thomas JW , Bouffard GG , Blakesley RW , Mullikin JC , Korlach J , Henderson DK , Frank KM , Palmore TN , Segre JA
Ref : Sci Transl Med , 6 :254ra126 , 2014
Abstract : Public health officials have raised concerns that plasmid transfer between Enterobacteriaceae species may spread resistance to carbapenems, an antibiotic class of last resort, thereby rendering common health care-associated infections nearly impossible to treat. To determine the diversity of carbapenemase-encoding plasmids and assess their mobility among bacterial species, we performed comprehensive surveillance and genomic sequencing of carbapenem-resistant Enterobacteriaceae in the National Institutes of Health (NIH) Clinical Center patient population and hospital environment. We isolated a repertoire of carbapenemase-encoding Enterobacteriaceae, including multiple strains of Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter cloacae, Citrobacter freundii, and Pantoea species. Long-read genome sequencing with full end-to-end assembly revealed that these organisms carry the carbapenem resistance genes on a wide array of plasmids. K. pneumoniae and E. cloacae isolated simultaneously from a single patient harbored two different carbapenemase-encoding plasmids, indicating that plasmid transfer between organisms was unlikely within this patient. We did, however, find evidence of horizontal transfer of carbapenemase-encoding plasmids between K. pneumoniae, E. cloacae, and C. freundii in the hospital environment. Our data, including full plasmid identification, challenge assumptions about horizontal gene transfer events within patients and identify possible connections between patients and the hospital environment. In addition, we identified a new carbapenemase-encoding plasmid of potentially high clinical impact carried by K. pneumoniae, E. coli, E. cloacae, and Pantoea species, in unrelated patients and in the hospital environment.
ESTHER : Conlan_2014_Sci.Transl.Med_6_254ra126
PubMedSearch : Conlan_2014_Sci.Transl.Med_6_254ra126
PubMedID: 25232178
Gene_locus related to this paper: 9entr-a0a0a0z8f2 , 9entr-a0a0a1azi2

Title : Drug development and PET-diagnostics for Alzheimer's disease - Schmidt_2005_Curr.Med.Chem_12_1677
Author(s) : Schmidt B , Braun HA , Narlawar R
Ref : Curr Med Chem , 12 :1677 , 2005
Abstract : The exact cause of Alzheimer's disease is still unknown; despite the dramatic progress in understanding. Most gene mutations associated with Alzheimer's disease point to the amyloid precursor protein and amyloid beta. The alpha-, beta- and gamma-secretases are the three executioners of amyloid precursor protein processing. Significant progress has been made in the selective inhibition of these proteases, regardless of the availability of structural information. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. Cholesterol lowering drugs and metal chelators are also in advanced clinical stages as disease modifiers. Successful trials demand either large cohorts or reliable markers for Alzheimer's disease. Therefore, several radiomarkers are under investigation to support such clinical trials.
ESTHER : Schmidt_2005_Curr.Med.Chem_12_1677
PubMedSearch : Schmidt_2005_Curr.Med.Chem_12_1677
PubMedID: 16022665

Title : Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats - Scali_2002_J.Neural.Transm_109_1067
Author(s) : Scali C , Casamenti F , Bellucci A , Costagli C , Schmidt B , Pepeu G
Ref : J Neural Transm , 109 :1067 , 2002
Abstract : The changes in extracellular acetylcholine levels were investigated by microdialysis in the cortex and hippocampus of aging rats after administration of metrifonate (80 mg/kg), rivastigmine (0.75 mg/kg), donepezil (1.5 mg/kg) or vehicle for 21 days (twice daily p.o.). Eighteen h after the last administration, cholinesterase inhibition was 85, 52 and 39% after metrifonate, rivastigmine and donepezil, respectively, and was accompanied by 988, 590 and 75% increase in cortical acetylcholine level. In the hippocampus, metrifonate and rivastigmine brought about a 169 and 108% increase in acetylcholine levels. A challenge dose of metrifonate, rivastigmine and donepezil was followed by a further increase in cortical and hippocampal acetylcholine levels. The retrograde perfusion of the M(2)-M(4) receptor antagonist AFDX-384 (10 microM) induced a 500 and 300% increase in cortical and hippocampal acetylcholine release, in control and rivastigmine-treated rats, respectively, no increase in metrifonate-treated rats, and a 210% increase in donepezil-treated rats. In conclusion, chronic treatment of aging rats with metrifonate, rivastigmine and donepezil induces a long-lasting increase in acetylcholine levels, and reveals marked differences between the three drugs.
ESTHER : Scali_2002_J.Neural.Transm_109_1067
PubMedSearch : Scali_2002_J.Neural.Transm_109_1067
PubMedID: 12111444

Title : Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats - Giovannini_1998_Eur.J.Pharmacol_354_17
Author(s) : Giovannini MG , Scali C , Bartolini L , Schmidt B , Pepeu G
Ref : European Journal of Pharmacology , 354 :17 , 1998
Abstract : The effects of 21-day treatment with the acetylcholinesterase inhibitors metrifonate (80 mg kg(-1) per os (p.o.)) and tacrine (3 mg kg(-1) p.o.), twice daily, on cortical and hippocampal cholinergic systems were investigated in aged rats (24-26 months). Extracellular acetylcholine levels were measured by transversal microdialysis in vivo; choline acetyltransferase and acetylcholinesterase activities were measured ex vivo by means of radiometric methods. Basal cortical and hippocampal extracellular acetylcholine levels, measured 18 h after the last metrifonate treatment, were about 15 and two folds higher, respectively, than in control and tacrine-treated rats. A challenge with metrifonate further increased cortical and hippocampal acetylcholine levels by about three and four times, respectively. Basal extracellular acetylcholine levels, measured 18 h after the last treatment with tacrine were not statistically different from those of the control rats. A challenge with tacrine increased cortical and hippocampal extracellular acetylcholine levels by about four and two times. A 75% inhibition of cholinesterase activity was found 18 h after the last metrifonate administration, while only a 15% inhibition was detectable 18 h after the last tacrine administration. The challenge with metrifonate or tacrine resulted in 90 and 80% cholinesterase inhibition, respectively. These results demonstrate that in aging rats a subchronic treatment with metrifonate results in a long-lasting, cholinesterase inhibition, and a persistent increase in acetylcholine extracellular levels which compensate for the age-associated cholinergic hypofunction. Metrifonate is therefore a potentially useful agent for the cholinergic deficit accompanying Alzheimer's disease.
ESTHER : Giovannini_1998_Eur.J.Pharmacol_354_17
PubMedSearch : Giovannini_1998_Eur.J.Pharmacol_354_17
PubMedID: 9726626

Title : Chronic nimodipine and acute metrifonate treatment decreases age- related cortical high voltage spindles in rats - Riekkinen_1997_Psychopharmacology_129_91
Author(s) : Riekkinen P, Jr. , Schmidt B , Jakala P , Koivisto E , Bjorklund M
Ref : Psychopharmacology , 129 :91 , 1997
Abstract : We studied the effect of nimodipine (1000 ppm mixed in food), an L-type calcium-channel antagonist, administered for 4 months, on the cortical EEG activity in young and aged rats. Nimodipine treatment decreased cortical high voltage spindles (HVSs) in aged rats, but did not prevent the diminution of spontaneous locomotor activity. The threshold dose of metrifonate, a cholinesterase inhibitor, for suppression of HVSs was lower in nimodipine compared to placebo treated aged rats (30 mg/kg versus 60 mg/kg; p.o.). In young rats, nimodipine did not decrease HVSs, protect from scopolamine (0.1 or 0.8 mg/kg, i.p.) induced EEG slowing or augment the effect of metrifonate to suppress slow waves induced by scopolamine. The present results suggest that a chronic nimodipine treatment modulates thalamocortical arousal and thereby adds to the therapeutic effects of metrifonate to restore normal cortical electrical arousal in aged rats.
ESTHER : Riekkinen_1997_Psychopharmacology_129_91
PubMedSearch : Riekkinen_1997_Psychopharmacology_129_91
PubMedID: 9122369

Title : Effects of metrifonate on radial arm maze acquisition in middle-aged rats - Dachir_1997_Brain.Res_777_251
Author(s) : Dachir S , Schmidt B , Levy A
Ref : Brain Research , 777 :251 , 1997
Abstract : The efficacy of metrifonate, a well-tolerated cholinesterase (ChE) inhibitor, in attenuating the normal aging- and corticosterone-induced impairments of radial maze performance of rats was compared. Middle-aged Fischer 344 rats were screened for their spatial orientation performance in the Morris water escape task. Good and bad performers were selected: good performers (N= 22) were treated with subcutaneous sustained-release corticosterone pellets, resulting in hippocampal cell damage and impaired spatial orientation in the radial maze; age-induced bad performers (N = 20) were tested without additional pharmacological intervention. Metrifonate (MFT), administered daily during radial maze testing, 30 min before training, at a dose of 15 mg/kg p.o., facilitated the acquisition of the task in age-impaired rats, but not in corticosterone-impaired rats.
ESTHER : Dachir_1997_Brain.Res_777_251
PubMedSearch : Dachir_1997_Brain.Res_777_251
PubMedID: 9449438

Title : Effects of combined chronic nimodipine and acute metrifonate treatment on spatial and avoidance behavior - Riekkinen_1997_Eur.J.Pharmacol_322_1
Author(s) : Riekkinen M , Schmidt B , Kuitunen J , Riekkinen P
Ref : European Journal of Pharmacology , 322 :1 , 1997
Abstract : The present experiment was designed to elucidate whether chronic dietary treatment with nimodipine (3 months, 1000 ppm) enhances water maze spatial navigation, passive avoidance behavior and locomotor activity, and whether such a treatment with nimodipine would interact with the therapeutic effect of acute metrifonate treatment. In young medial septum-lesioned rats, nimodipine had no effect by its own on cognitive or motor behavior, and did not enhance the water maze and passive avoidance behavior improving action of metrifonate (3 and 10 mg/kg. p.o.). Nimodipine treatment of aged rats did not markedly affect the deficit in motor performance. Single and combined nimodipine and metrifonate (3 and 10 mg/kg, p.o.) treatment of aged rats resulted in shorter escape distance values to the hidden water maze escape platform compared to those of control aged rats. The passive avoidance performance of aged rats was more effectively facilitated by a combined nimodipine and metrifonate treatment than by either of the drugs on their own. Following a washout period of 2.5 months the rats that were treated previously with nimodipine no longer performed better than aged controls in the water maze test. Furthermore, after the washout period metrifonate 10 mg/kg was no longer effective in improving the water maze behavior of the now 26-month-old rats irrespective of their chronic pretreatment. Taken together, these findings indicate that chronic nimodipine and acute metrifonate treatment may more effectively stimulate cognitive functioning than either of the treatments on their own.
ESTHER : Riekkinen_1997_Eur.J.Pharmacol_322_1
PubMedSearch : Riekkinen_1997_Eur.J.Pharmacol_322_1
PubMedID: 9088863

Title : Behavioral characterization of metrifonate-improved acquisition of spatial information in medial septum-lesioned rats - Riekkinen_1997_Eur.J.Pharmacol_323_11
Author(s) : Riekkinen P, Jr. , Schmidt B , Riekkinen M
Ref : European Journal of Pharmacology , 323 :11 , 1997
Abstract : We investigated the effects of acute oral pretraining treatment with an indirect acetylcholinesterase inhibitor, metrifonate, on water maze spatial navigation in medial septum-lesioned rats. We observed that metrifonate (30 mg/kg, orally) (1) does not alter the pattern of exploration of lesioned rats at the water maze pool or retrieval of spatial memory, (2) effectively reverses the acquisition defect, (3) enhances reversal learning, and (4) improves acquisition of water maze navigation by facilitating the encoding of the spatial representation of a specific environment. These results indicate that metrifonate does not improve escape performance to the hidden platform by modulating exploration strategy, but that metrifonate enhances the speed and accuracy of development and durability of spatial memory engrams, and facilitates learning capacity that depends on activity of the septo-hippocampal projection.
ESTHER : Riekkinen_1997_Eur.J.Pharmacol_323_11
PubMedSearch : Riekkinen_1997_Eur.J.Pharmacol_323_11
PubMedID: 9105871

Title : Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats - Scali_1997_Eur.J.Pharmacol_325_173
Author(s) : Scali C , Giovannini MG , Bartolini L , Prosperi C , Hinz V , Schmidt B , Pepeu G
Ref : European Journal of Pharmacology , 325 :173 , 1997
Abstract : The effects of metrifonate were investigated in 4-6- and 22-24-month-old rats. Extracellular acetylcholine levels were measured by transversal microdialysis in vivo. Baseline extracellular acetylcholine levels in the cerebral cortex and hippocampus were 42% and 60% lower, respectively, in old than in young rats. Old rats did not discriminate between familiar and novel objects. In old rats, metrifonate (80 mg/kg p.o.) brought about 85% inhibition of cholinesterase activity in the cortex and hippocampus, a 4-fold increase in extracellular acetylcholine levels in the cortex only, and restored object recognition. In young rats, metrifonate caused 75% cholinesterase inhibition in the cerebral cortex and hippocampus, a 2-fold increase in cortical and hippocampal extracellular acetylcholine levels, and no effect on object recognition. The slight cholinesterase inhibition following metrifonate (30 mg/kg) in aged rats had no effect on cortical acetylcholine levels and object recognition. In conclusion, metrifonate may improve the age-associated cholinergic hypofunction and cognitive impairment.
ESTHER : Scali_1997_Eur.J.Pharmacol_325_173
PubMedSearch : Scali_1997_Eur.J.Pharmacol_325_173
PubMedID: 9163564

Title : Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits - Kronforst-Collins_1997_Pharmacol.Biochem.Behav_56_103
Author(s) : Kronforst-Collins MA , Moriearty PL , Ralph M , Becker RE , Schmidt B , Thompson LT , Disterhoft JF
Ref : Pharmacology, Biochemistry & Behavior , 56 :103 , 1997
Abstract : The cholinergic system is known to show deterioration during aging and Alzheimer's disease. In response, a therapeutic approach to Alzheimer's disease has been to attempt to compensate for the decrease in central cholinergic function by potentiating the activity of the remaining intact cholinergic cells with cholinesterase inhibitors. In this study treatment with the long-lasting cholinesterase inhibitor metrifonate enhanced acquisition of eyeblink conditioning in aging rabbits without producing interfering side effects. The effects of metrifonate on central and peripheral cholinesterase activity were evaluated, as was the involvement of plasma atropine esterase activity on the central and peripheral response to metrifonate. Results demonstrate that metrifonate can produce predictable, dose-dependent ChE inhibition. Associative learning in the aging rabbit was improved by metrifonate-induced steady state ChE inhibition within a range of 30-80%. Metrifonate was behaviorally effective in the absence of the severe side effects which typically plague cholinesterase inhibitors, suggesting that metrifonate is a possible treatment for the cognitive deficits resulting from normal aging and Alzheimer's disease.
ESTHER : Kronforst-Collins_1997_Pharmacol.Biochem.Behav_56_103
PubMedSearch : Kronforst-Collins_1997_Pharmacol.Biochem.Behav_56_103
PubMedID: 8981616

Title : Metrifonate improves associative learning and retention in aging rabbits - Kronforst-Collins_1997_Behav.Neurosci_111_1031
Author(s) : Kronforst-Collins MA , Moriearty PL , Schmidt B , Disterhoft JF
Ref : Behavioral Neuroscience , 111 :1031 , 1997
Abstract : The cholinergic system is known to show deterioration during aging and Alzheimer's disease (AD). In response, a therapeutic approach to AD has been to attempt to compensate for the decrease in central cholinergic function by potentiating the activity of the remaining intact cholinergic cells with cholinesterase (ChE) inhibitors. In this study treatment with the long-lasting ChE inhibitor metrifonate facilitated acquisition and retention of eyeblink conditioning in aging rabbits. Metrifonate treatment resulted in steady-state, dose-dependent acetylcholinesterase (AChE) inhibition in red blood cells. Maximal behavioral efficacy was achieved with AChE inhibition of approximately 40%, with no further improvements resulting from increased levels of inhibition. Metrifonate was behaviorally effective in the absence of the severe side effects that can plague ChE inhibitors, supporting metrifonate as a possible treatment for the cognitive deficits resulting from normal aging and AD.
ESTHER : Kronforst-Collins_1997_Behav.Neurosci_111_1031
PubMedSearch : Kronforst-Collins_1997_Behav.Neurosci_111_1031
PubMedID: 9383522

Title : Effects of combined nimodipine and metrifonate on rat cognition and cortical EEG - Jakala_1996_Eur.J.Pharmacol_318_239
Author(s) : Jakala P , Riekkinen M , Bjorklund M , Koivisto E , Schmidt B , Riekkinen P, Jr.
Ref : European Journal of Pharmacology , 318 :239 , 1996
Abstract : The present study investigated if short-term treatment with an L-type Ca2+-channel inhibitor, nimodipine, can stimulate cognitive functioning and cortical electroencephalograph (EEG) arousal, and potentiate the effect of a cholinesterase inhibitor, metrifonate. Pretraining administration of nimodipine (3, 10 and 30 mg/kg, p.o.) had no effect on water maze and passive avoidance behavior of young neurologically intact controls, or water maze and passive avoidance performance failure induced by scopolamine pretreatment (i.p.; 0.4 mg/kg during the water maze and 2.0 mg/kg during the passive avoidance study), medial septal lesioning, or aging. Furthermore, nimodipine (3, 10 and 30 mg/kg, p.o.) had no effect on the improvement by metrifonate (10 mg/kg, p.o.) of the water maze and passive avoidance failure induced by scopolamine pretreatment or medial septal lesioning, nor did it affect the potential of metrifonate (30 mg/kg. p.o.) to improve the water maze or passive avoidance behavior of aged rats. Finally, nimodipine (3, 10 and 30 mg/kg, p.o.) had no effect on spontaneously occurring thalamically generated neocortical high-voltage spindles or spectral EEG activity of young controls, nor did it alleviate the spectral EEG abnormality induced by scopolamine (0.2 mg/kg, i.p.) administration. Also, the combination of nimodipine 3 or 10 mg/kg and a subthreshold dose of metrifonate 10 mg/kg could not suppress high-voltage spindles or scopolamine treatment-induced spectral EEG activity abnormalities. According to the present results, short-term treatment with nimodipine does not stimulate cognitive functions or increase cortical EEG arousal, and does not block or potentiate the propensity of metrifonate to improve cognitive performance of rats.
ESTHER : Jakala_1996_Eur.J.Pharmacol_318_239
PubMedSearch : Jakala_1996_Eur.J.Pharmacol_318_239
PubMedID: 9016911

Title : An indirect cholinesterase inhibitor, metrifonate, increases neocortical EEG arousal in rats - Bjorklund_1996_Neuroreport_7_1097
Author(s) : Bjorklund M , Jakala P , Schmidt B , Riekkinen M , Koivisto E , Riekkinen P, Jr.
Ref : Neuroreport , 7 :1097 , 1996
Abstract : We investigated the ability of a cholinesterase inhibitor, metrifonate, to desynchronize cortical EEG activity. Metrifonate suppressed immobility-related high voltage spindling activity in young and aged rats at doses of 30 and 60 mg kg-1, p.o., and 10, 30 and 60 mg kg-1, p.o., respectively. The increase in EEG 1-20 Hz amplitude induced by scopolamine (0.2 mg kg-1, i.p.) was fully alleviated by metrifonate (30 and 100 mg kg-1, p.o.) and partially alleviated by a reference cholinesterase inhibitor, THA (3 and 6 mg kg-1, i.p.). Nucleus basalis (NB) lesions induced by quisqualic acid decreased frontal cortical choline acetyltransferase activity by 80% and increased cortical EEG slow waves. Metrifonate and THA did not reverse NB lesion-induced EEG abnormality. We conclude that metrifonate enhances cholinergic desynchronization of cortical EEG waves and that a severe defect of presynaptic NB cholinergic fibres limits the therapeutic effects of metrifonate.
ESTHER : Bjorklund_1996_Neuroreport_7_1097
PubMedSearch : Bjorklund_1996_Neuroreport_7_1097
PubMedID: 8804059

Title : Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats - Riekkinen_1996_Eur.J.Pharmacol_309_121
Author(s) : Riekkinen P, Jr. , Schmidt B , Stefanski R , Kuitunen J , Riekkinen M
Ref : European Journal of Pharmacology , 309 :121 , 1996
Abstract : We investigated the effects of acute p.o. pretraining treatment with an indirect acetylcholinesterase inhibitor, metrifonate, on water maze spatial navigation and passive avoidance behavior. Metrifonate (10-100 mg/kg, orally, p.o.) did not improve the water maze or passive avoidance performance of young intact rats. However, in young rats metrifonate over a broad dosage range (10-100 mg/kg, p.o.) was able to alleviate the adverse effects of scopolamine (a muscarinic acetylcholine receptor antagonist; 0.4 and 2.0 mg/kg in water maze and passive avoidance study, respectively) and medial septum-lesioning on spatial reference and working memory and passive avoidance performance. In old (23-month-old) rats, a defect of water maze and passive avoidance behavior was observed. In old rats, metrifonate improved spatial reference memory function in the water maze and also passive avoidance at 10-30 mg/kg, but the 3 mg/kg dose was ineffective. Very old (27-month-old) rats had a more severe impairment of water maze performance than old rats, and metrifonate 3-30 mg/kg did not improve their spatial navigation. These results show that metrifonate may over a wide range of doses stimulate cognitive functioning, but during advanced aging neurobiological defects develop that may mask some of the therapeutic effects of metrifonate in rats.
ESTHER : Riekkinen_1996_Eur.J.Pharmacol_309_121
PubMedSearch : Riekkinen_1996_Eur.J.Pharmacol_309_121
PubMedID: 8874130

Title : Pseudomonas lemoignei has five poly(hydroxyalkanoic acid) (PHA) depolymerase genes: a comparative study of bacterial and eucaryotic PHA depolymerases. -
Author(s) : Briese BH , Schmidt B , Jendrossek D
Ref : J Environ Polym Degrad , 2 :75 , 1994
PubMedID:
Gene_locus related to this paper: psele-PHAZ2 , psele-PHAZ3

Title : Identification and molecular characterization of the Alcaligenes eutrophus H16 aco operon genes involved in acetoin catabolism - Priefert_1991_J.Bacteriol_173_4056
Author(s) : Priefert H , Hein S , Krueger N , Zeh K , Schmidt B , Steinbuechel A
Ref : Journal of Bacteriology , 173 :4056 , 1991
Abstract : Acetoin:dichlorophenolindophenol oxidoreductase (Ao:DCPIP OR) and the fast-migrating protein (FMP) were purified to homogeneity from crude extracts of acetoin-grown cells of Alcaligenes eutrophus. Ao:DCPIP OR consisted of alpha and beta subunits (Mrs, 35,500 and 36,000, respectively), and a tetrameric alpha 2 beta 2 structure was most likely for the native protein. The molecular weight of FMP subunits was 39,000. The N-terminal amino acid sequences of the three proteins were determined, and oligonucleotides were synthesized on the basis of the codon usage of A. eutrophus. With these, the structural genes for the alpha and beta subunits of Ao:DCPIP OR and FMP, which were referred to as acoA, acoB, and acoC, respectively, were localized on one single EcoRI restriction fragment which has been cloned recently (C. Frnd, H. Priefert, A. Steinbchel, and H. G. Schlegel, J. Bacteriol. 171:6539-6548, 1989). The nucleotide sequences of a 5.3-kbp region of this fragment and one adjacent fragment were determined, and the structural genes for acoA (1,002 bp), acoB (1,017 bp), and acoC (1,125 bp) were identified. Together with the gene acoX, whose function is still unknown and which is represented by a 1,080-bp open reading frame, these genes are probably organized in one single operon (acoXABC). The transcription start site was identified 27 bp upstream of acoX; this site was preceded by a region which exhibited complete homology to the enterobacterial sigma 54-dependent promoter consensus sequence. The amino acid sequences deduced from acoA and acoB for the alpha subunit (Mr, 35,243) and the beta subunit (Mr, 35,788) exhibited significant homologies to the primary structures of the dehydrogenase components of various 2-oxo acid dehydrogenase complexes, whereas those deduced from acoC for FMP (Mr, 38,941) revealed homology to the dihydrolipoamide acetyltransferase of Escherichia coli. The occurrence of a new enzyme type for the degradation of acetoin is discussed..
ESTHER : Priefert_1991_J.Bacteriol_173_4056
PubMedSearch : Priefert_1991_J.Bacteriol_173_4056
PubMedID: 2061286
Gene_locus related to this paper: cupnh-acoc